Teva Pharmaceutical Industries Ltd.(NASDAQ:TEVA) says it has chosen Vice Chairman, Dr. Phillip Frost to serve as chairman of its Board of Directors.Teva Pharmaceutical Industries Ltd trades on the “NASDAQ” under the stock symbol “TEVA”. For the Latest information regarding “TEVA”, make sure to visit the Most Exclusive and In Depth newsletter website at: http://www.wallstreetgrand.com/.
Join today and be part of the best free investment newsletter on the web where we focus on market moving news.
Generic Drug maker, Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) says it has chosen Vice Chairman, Dr. Phillip Frost to serve as chairman of its Board of Directors. The company headquartered out of Israel said Tuesday that Frost will replace Moshe Many, who had been serving as short-term chairman and will now serve as Vice Chairman. The moves came as Teva said former Chairman Eli Hurvitz told the company that he wants to be released from his duties at Teva in order to focus on his full recovery.
About Teva:
Teva Pharmaceutical Industries Limited engages in the development, production, and sale of a range of generic and branded pharmaceuticals, biogenerics, and active pharmaceutical ingredients (APIs) worldwide. The company’s principal products include Copaxone for multiple sclerosis; and Azilect for Parkinson’s disease. Teva Pharmaceutical also provides specialty pharmaceutical products, which include respiratory products based on its proprietary delivery systems, including Easi-Breathe, an advanced breath-activated inhaler; Spiromax/Airmax, a multidose dry powder inhaler; Steri-Nebs, the blow-fill-seal based nebulizers; and Cyclohaler, a single dose dry powder device. The company’s branded respiratory products include ProAir, a short-acting beta-agonist for the treatment of bronchial spasms and exercise-induced bronchospasm; and Qvar, an inhaled corticosteroid for long-term control of chronic bronchial asthma. In addition, it offers APIs for respiratory, cardiovascular, anti-cholesterol, central nervous system, dermatological, hormones, anti-inflammatory, oncology, immunosuppressants, and muscle relaxants. Further, the company provides women’s health care products, such as oral contraceptives, intrauterine contraception, and hormone therapy treatments for menopause/perimenopause, as well as therapies for use in infertility and urinary incontinence. It also holds a biotechnology platform focused on the development of peptide and protein-based medicines. Teva Pharmaceutical has cooperation agreements with Kowa Company, Ltd.; Lonza Group Ltd.; H. Lundbeck A/S; Impax Laboratories, Inc.; Anchen Pharmaceuticals, Inc.; sanofi-aventis; and OncoGenex Pharmaceuticals. The company was founded in 1901 and is headquartered in Petach Tikva, Israel.
You can contact us during market hours at 1-888-9-ClubGrand (1888-925-8247) or via email at staff@wallstreetgrand.com.
Safe Harbor
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act") including 2009 growth, revenue for the second quarter and year of 2009 and gross margin for the second quarter and year of 2009. Additionally, words such as "seek," "intend," "believe," "plan," "estimate," "expect," "anticipate" and other similar expressions are forward-looking statements within the meaning of the Act. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the impact of intense competition, the continuation or worsening of current economic conditions and the condition of the domestic and global credit and capital markets.
Disclaimer:
Wall Street Grand LLC has not been compensated by the company for this press release and does not expect to be compensated in the future for any type of awareness. To read our full disclaimer clicks the link http://www.wallstreetgrand.com/disclosure.html.
